Table 3.
Post Randomization Factors Stratified by Group
| Factor | Caspofungin (n = 144) | Combined Triazole (n = 146) | Fluconazole (n = 100) | Voriconazole (n = 46) |
|---|---|---|---|---|
| Median days on protocol prophylaxis (range) | 29.5 (0–44) | 28.5 (0–45) | 30 (0–44) | 23 (0–45) |
| Patients receiving other antifungal therapy during protocol-assigned therapy period, n (%) | 24 (16.7%) | 33 (22.6%) | 27 (27%) | 6 (13%) |
| ANC recovery at day 42 (95% CI) | 97.9% (92.7%–99.5%) | 93.8% (89.0%–96.9%) | 94% (86.2%–97.5%) | 93.1% (83.2%–98.2%) |
| Median days to ANC recovery from HCT (IQR)a | 18 (15, 22) | 17 (14, 23) | 18.5 (16, 25) | 14 (11, 18) |
| Patients receiving systemic corticosteroids (through day 100 or end of IFD monitoring), n (%) | 91 (63.2%) | 95 (65.1%) | 63 (63%) | 32 (69.6%) |
| Percent of days on systemic corticosteroids (through day 100 or end of IFD monitoring) (IQR)b | 21% (6, 51) | 38% (11, 60) | 24% (6, 53) | 49% (20, 70) |
Abbreviations: IFD, invasive fungal disease; CI, confidence interval; ANC, absolute neutrophil count; HCT, hematopoietic cell transplant; IQR, interquartile range.
aFor those patients who recovered by Day 42.
bFor those patients who received systemic corticosteroids.